An independent resource

About

Long Waypoint 24 is an independent information resource focused on ibogaine and traumatic brain injury. Our aim is to present evolving evidence, the legal landscape, and safety considerations with plain language and careful sourcing so people affected by TBI and their families can find measured context.

Mission

Lucent Cairn helps people understand the evolving evidence, legal status, and serious safety considerations around ibogaine for traumatic brain injury. We emphasize uncertainty and safety.

Audience

For people affected by TBI, veterans, families, and clinicians seeking careful context rather than clinical guidance.

Values

Independence, evidence before claims, safety awareness, plain language, respect for uncertainty.

Close-up detail view related to ibogaine treatment and traumatic brain injury, editorial photograph showing clinical textures

Our editorial approach

We collect, summarize, and contextualize publicly available sources so readers can see what is known, uncertain, and disputed. Our work is organized by topic areas (legal status, safety, evidence summaries, and research priorities) and is designed to be navigable for non-specialist readers and for clinicians seeking references.

We draw on registries and peer-reviewed literature, and we reference authoritative institutions when possible; for example, general claims about clinical trial registration practices are grounded in established guidance such as ClinicalTrials.gov (ClinicalTrials.gov trial registry) and principles of evidence synthesis described by academic sources like the Cochrane Collaboration (Cochrane Library).

What we cover

In general terms we summarize published studies, legal summaries, safety reports, and proposals for future research. We also explain how different kinds of evidence (case reports, small trials, registry signals) fit together and what limits they carry for people considering investigational treatments.

How we source and vet information

Our editorial checks include cross-referencing primary publications, looking for trial registration entries, and verifying regulatory statements from official sources such as the U.S. Food and Drug Administration when applicable (U.S. FDA). We do not perform original clinical trials; instead, we synthesize and annotate the existing public record and flag where evidence is preliminary.

Editorial principles

  • Independence: we do not accept clinical referrals or treatment commissions.
  • Evidence before claims: we privilege peer-reviewed and registered evidence.
  • Safety awareness: we highlight harms, contraindications, and uncertainty.
  • Plain language: complex methods are explained for non-specialists.
  • Respect for uncertainty: we avoid strong claims where evidence is weak.

Who this is for

This resource is for people impacted by traumatic brain injury, caregivers, clinicians seeking context, and anyone weighing investigational options. If you are exploring services, our Services page describes the kinds of informational support and literature summaries we provide rather than clinical offerings; for a broader organizational entry point see our main site at Long Waypoint 24’s homepage.

Independent by design

Long Waypoint 24 is intentionally not a treatment provider. The content here is informational only and is not medical or legal advice. For questions about medical care, please consult licensed healthcare professionals and official guidance from regulatory bodies.

FAQ

Is Long Waypoint 24 a clinic?

No. Long Waypoint 24 is an independent information resource and is not a clinic, medical provider, or licensed treatment center. Our footer also restates this disclosure.

Where do you get your evidence?

We collect peer-reviewed studies, trial registry entries, regulatory statements, and public safety reports, and we cross-check these with institutional resources such as registry databases (ClinicalTrials.gov) and recognized evidence-synthesis organizations like Cochrane (Cochrane Library).

How can I use the site?

Use the site to orient yourself to the kinds of evidence and safety conversations that surround investigational treatments. For service-oriented listings we sometimes reference third-party directories; readers exploring practical options may consult reputable registries and directories such as the informational ibogaine treatment US directory alongside official clinical guidance.